Phaseline

Targets › NGFR

NGFR (Tumor necrosis factor receptor superfamily member 16): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 2; Ophthalmology, Oncology; next expected readout Mar 2027.

Low affinity receptor which can bind to NGF, BDNF, NTF3, and NTF4. Forms a heterodimeric receptor with SORCS2 that binds the precursor forms of NGF, BDNF and NTF3 with high affinity, and has much lower affinity for mature NGF and BDNF. Plays an important role in differentiation and survival of specific neuronal populations during development (By similarity). (UniProt, P08138)

Open in Phaseline: the race on NGFR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of South FloridaAcoltremon 0.003% ophthalmic solution
Recombinant human nerve growth factor (NGF)
NGFRPhase 4Ocular Surface DiseaseMar 2027
Benedetto FalsiniCHF6467
Nerve growth factor (NGF) agonist; binds trkA (NTRK1) receptor with high affinity and p75N
NGFR, NTRK1Phase 2Optic Pathway GliomaJun 2027

Conditions

Ocular Surface Disease (1) Optic Pathway Glioma (1)

Modalities

small molecule (2)

Companies

University of South Florida (1) Benedetto Falsini (1)

Related targets

NTRK1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.